Zydus Lifesciences share price gained in the opening trade on September 5 after the company's wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules for the US market.
At 09:19am, Zydus Lifesciences was quoting at Rs 1,020.00, up Rs 8.00, or 0.79 percent, on the BSE.
Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis.
Catch all the market action on our live blog
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product, and thereafter, for the manufacture and supply of the product.
Zydus will be responsible for the commercialization of the product in the USA.
As one of the first filers, Synthon has received tentative approval within 30 months from US Food and Drug Administration (FDA), making the product eligible for a shared 180-day exclusivity upon market entry.
"This collaboration with Synthon enables us to bring this important treatment to the U.S. market. This collaboration reinforces our strategic focus on advancing care in therapeutic areas and reflects our commitment to making essential medicines more accessible to patients,” said Punit Patel, President and Chief Executive Officer of Zydus Pharmaceuticals (USA) Inc.
Earlier in this month the company announced the launch of its trivalent influenza (Flu) vaccine VaxiFluTM introduced for the first time in India, aligning with the global recommendations of WHO.
In August Zydus Therapeutics, a wholly owned subsidiary, announced positive topline results from the pivotal EPICS-III Phase 2(b)/3 clinical trial.
The company announced a 3.3% year-on-year increase in consolidated net profit to Rs 1,466.8 crore for the first quarter of FY26, while revenue from operations grew by 5.9% to Rs 6,573.7 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
